Screening procedures currently used in Australian blood banks minimise transfusion-transmitted infection. The risk of acquiring any infection in this manner may be less than 0.1%.
A signed declaration form and private interview were introduced late in 1984 and towards the end of that year, heat treatment of Factor VIII to inactivate the HIV virus was introduced by CSL. Screening with an ELISA assay commenced in all blood banks throughout Australia on 1 May 1985 , Since that time there has been no known case of transmission of HIV through blood transfusion in Australia. All donations are tested, regardless of the number of times a donor has donated previously. Each donation is initially tested once by the ELISA screening test, and if positive, the test is repeated again in replicate. If one of the replicate tests is positive then that donation is regarded as repeatably reactive and undergoes confirmatory testing by Western Blot. Any donation which is found to be repeat reactive is discarded.
In the first five and a half years of screening in Australia, 46 positive donors were found amongst over five million donations giving an overall incidence of 0.86 per 100,000 donations. 7 The highest recorded rate was in New South Wales with 1.5 per 100,000.
A test for the second virus capable of causing AIDS, HIV-2, is now also performed on all donated units. This virus was discovered in 1985 at the Pasteur Institute in Paris in the sera of two West African patients with AIDS. 8 It has considerable homology to HIV-l but appears to be less pathogenic. The introduction of this test in the form of a combination test kit, where both HIV-l and HIV-2 antibodies are screened for in a single ELISA test, followed the report of the first HIV-2 positive person in Australia in 1992. 9 These combination tests, as well as screening for both HIV-l and HIV-2, have increased sensitivity for HIV-l antibody. 10 Whilst all donors go through the rigorous screening and testing described above, there is still a theoretical risk of HIV transmission in the "window period", that is before the donor has made detectable antibodies. Whilst this has not occurred in Australia to our knowledge, experience in other countries shows that it can happen. In the United States it is estimated that from screened blood products there is a risk of one in 40,000 donations transmitting HIV. 1112 By 1988 the Centres for Disease Control in Atlanta had reported transmission of HIV to 13 recipients from seven blood donors screened as HIV negative at donation. 11 Transmission has also been reported in the United States in multiple recipients of organs from a seronegative but infective donor. 13 The possibility of transmission raises the question as to whether there are any other mechanisms for detecting the virus. Theoretically antigenemia could be detected prior to the development of antibody; however, several large studies have looked at this and found there were no additional HIV infected donors found through testing for the p24 antigen. 14.15 This issue remains controversial as there have been reports of HIV transmission from donors who have later been found to have been p24 antigen positive. 16 Interestingly, p24 antigen testing has been introduced in Thailand in an attempt to counter the problems created by the rapid spread of HIV in that country. 17 A number of other surrogate markers have been suggested including serum neopterin, hepatitis B core antibody and screening for syphilis. 18.19 Confidential unit exclusion, which involves a donor indicating their donation should not be used for transfusion, has also been suggested, but this is also controversial. 20.21 
HEPATITIS VIRUSES
Hepatitis has been the most common cause of posttransfusion infection, and even with the recent introduction of hepatitis C screening, it is likely that it remains the most frequent infective complication of a blood transfusion.
The list of hepatitis viruses continues to grow as exemplified by the recent discoveries of hepatitis C and E. 22.23 The following is an outline of the role which each of the hepatitis viruses plays in transfusion transmitted hepatitis.
Hepatitis A
Hepatitis A is not generally considered a problem in transfusions of blood as there is no carrier state and the period of infectivity prior to clinical symptoms is usually only days to a few weeks. Parenteral transmission can occur however, and there are a small number of reports of transmiSSIOn through blood transfusion. 2420 The only means of prevention of transfusion-transmitted hepatitis A is to carefully question donors about signs or symptoms of current illness.
Hepatitis B
The introduction of hepatitis B surface antigen (HBsAg) testing into Australian blood banks in 1970 made Australia the first country to universally test all blood donations. Prior to the introduction of hepatitis C screening (see below), hepatitis B still accounted for 5070 to 10070 of transfusion-associated hepatitis. Transmission of hepatitis B was therefore still occurring in spite of the very sensitive assays for HBsAg. In fact, the percentage of cases of post-transfusion hepatitis due to hepatitis B has probably increased due to the reduction in non-A non-B hepatitis through hepatitis C screening.
Even though all donors are asked about a history of hepatitis, infective donors can be missed in two circumstances. Firstly, a donor may have HBsAg at a level below that which can be detected by testing. Secondly, the donor may be in the so called' 'window period", the period where the donor has lost detectable HBsAg but has not yet become noninfectious. A number of countries test for hepatitis B core antibody (anti-HBc) in an endeavour to detect donors in the above categories, but this practice remains controversial and the currently available anti-HBc assays have poor specificity. 28 The majority of anti-HBc positive donors will either be hepatitis B surface antibody positive indicating immunity or HBsAg-positive indicating they are infectious. Thus, it is the donor who has anti-HBc only who needs to be found and, unfortunately, in this situation the assay has an 86070 false-positive rate. 28 Currently three New South Wales donations per 10,000 are positive for HBsAg and this incidence is increasing slowly with the influx of immigrants, particularly from Asia. In spite of these problems in detecting every infective donor the combination of donor interviewing and laboratory screening is extremely effective and the risk of transfusion-transmitted hepatitis B is extremely low.
Hepatitis C Virus
Hepatitis C makes up the majority of what was formerly called non-A non-B hepatitis. For the last two decades non-A non-B hepatitis has been the commonest infectious complication of blood transfusion. A study in the early 1980s involving the New South Wales Blood Transfusion Service showed that approximately 1.7070 of cardiac surgery patients transfused developed biochemical or clinical evidence of non-A non-B hepatitis. 29 A more recent study by the same group, which is currently being prepared for publication, shows that due to other measures such as the introduction of private interviews and the Donor Declaration Form, the incidence of non-A non-B hepatitis fell by approximately one half during the 1980s. 3o In 1989 the identification of a virus thought to be the cause of up to 90070 of non-A, non-B hepatitis marked a major breakthrough. 22 Antibody tests to this new virus, termed hepatitis C, were rapidly developed. 1 1.l 2 The remarkable fact behind these developments is that although DNA derived from hepatitis C virus suggested it to be a flavi-like virus, the virus itself has yet to be visualised or propagated. First generation hepatitis C antibody tests were introduced into all Australian blood banks in February 1990, making Australia the second country, after Japan, to introduce screening on all blood donations.
The initial high false-positive rate of 70070 to 80070 has fallen and currently using second-generation ELISA tests with multiple antigens approximately 0.3070 of Sydney blood donations are found to be reactive, while just under 0.1 070 of donors in New South Wales are confirmed positive using the RIBA confirmatory test.
It is difficult to estimate the current risk of developing hepatitis C following blood transfusion in Australia. We know that even before the introduction of hepatitis C testing the incidence was already low, and clearly screening will greatly reduce this risk even further. 30 The risk is now likely to be so low that it will be difficult to carry out a large enough study for it to be established.
Delta Agent (Hepatitis DJ
The Delta Agent is a defective RNA virus which is dependent on hepatitis B virus for replication. An infection with delta agent or hepatitis D may occur concurrently with hepatitis B (co-infection) or in a carrier of hepatitis B (superinfection). Transmission routes are similar to hepatitis B. 11.14 It is endemic in southern Italy and more recently it has been shown to have a fairly global distribution, although it is not documented to have been a problem in blood transfusion in Australia. Prevention of transmission of the delta agent through transfusion is accomplished through testing for HBsAg.
Hepatitis E
Hepatitis E is the cause of what was formerly described as the epidemic form of non-A non-B hepatitis. 13 To date epidemics have occurred in the third world but not in Australia or other developed countries.
The mode of spread of hepatitis E is similar to hepatitis A, but it seems to affect adults rather than children. Hepatitis E could theoretically be transmitted by transfusion, but to date there have been no reported cases.
SYPHILIS
Blood banks have screened for syphilis for decades and transfusion-transmitted syphilis is very uncommon. Recently, however, it has become a controversial issue in blood transfusion. The American Association of Blood Banks (AABB) dropped the requirement for syphilis screening several years ago as transmission was so rare. The organism, Treponema pallidum, is more likely to be present in the blood during the seronegative phase of syphilis than the seropositive phase. Thus routine syphilis screening does not ensure against transfusion-transmitted syphilis. Further T. pallidum is eliminated by refrigeration at 4°C. However, the Food and Drug Administration, which never dropped syphilis testing as a requirement, have stated that consideration should be given to using syphilis screening as an additional surrogate test for AIDS in order to further improve the detection of persons at risk for HIy'l;Jo The AABB has now once again made syphilis screening a mandatory requirement. 17 The known high incidence of biological false positives would seem to make screening for syphilis a dubious surrogate test to detect HIV carriers. Further, although there is data to support the legitimacy of syphilis screening as a surrogate test for HIV in STD clinics, there is no conclusive evidence in volunteer blood donors who are a vastly different group.
There has been no known transmission of syphilis by blood transfusion in Australia for over two decades.
MALARIA
In spite of the eradication programme by the World Health Organisation in the 1950s, malaria has again become a global health problem. Plasmodium jalciparum, vivax, ovale and malariae may all be transmitted by blood transfusion. Air travel has meant that the incubation period may not even be completed by the time an infected traveller returns home while immunity and prophylactic drug treatment lengthen the incubation time. In 1983 it was estimated that the risk of transfusion-transmitted malaria in the United States was 0.25 cases for everyone million units of blood collected. 38 Anaesthesia and Intensive Care, Vol. 21, No. I, February, 1993 In Australia there were over 350 cases of malaria reported in 1991 but transfusion-transmitted malaria is a very rare event. 39 In Australia, donors returning from endemic areas cannot donate cellular products for 12 months. This increases to two years if chemoprophylaxis was taken. A recent case of transfusiontransmitted P. Ja/ciparum in Victoria is believed to be the first transfusion-transmitted malaria case for over 20 years in Australia. 40 In transfusion-transmitted malaria, red cells containing the parasites enter the circulation directly, bypassing the normal exoerythrocyte stage in the life cycle of plasmodium. Because of this relapses do not occur in transfusion-transmitted disease. 41 Although cell-free blood components are believed to be free from risk, transmission has been reported from cryoprecipitate as well as red cells, platelets and white cell concentrates. 42 Transmission has even been reported from frozen red cells after thawing and washing. 43 Diagnosis is best made by careful examination of blood films although indirect fluorescent antibody testing, if available, may have a role especially in investigating donors for current or previous malarial infection. 44 There is no doubt that current exclusion criteria are very effective and will be difficult to improve without good screening tests becoming available. Physicians do, however, need to be aware, or at least consider the diagnosis, of transfusion-transmitted malaria in any patient with fever who has recently had a blood transfusion.
HTLV-I
HTLV-I is a retrovirus related to HIV and was first isolated in 1980 from a patient with cutaneous T-cell lymphoma. 45 It does not cause AIDS but in approximately one per cent of persons infected it may cause either adult T-cell leukaemia or Tropical Spastic Paraparesis, a chronic and potentially fatal neurological condition. It is endemic in Japan, the Caribbean, Africa and parts of Papua New Guinea, but has also now been reported in many other parts of the world. 46 ,47 In parts of southern Japan up to 15070 of the population carry antibodies to the virus. 46 Recent evidence also indicates that this virus is endemic in some Aboriginal groups within Australia and areas of the Western Pacific .• ',49,50 Blood Transfusion Services throughout Australia have introduced screening of people who have travelled or who have parents or sexual partners who have travelled to high-risk areas. The Australian Red Cross Society has also funded screening of all blood donations in the Northern Territory as a national study. This limited screening has now identified four blood donors Anaesthesia and Intensive Care, Vol. 21, No. I, February, 1993 with evidence of HTLV-I infection. 51 HTLV-I is not known to have been transmitted through blood transfusion in Australia, but a recent Australian study did find one of 202 haemophiliacs to have evidence of HTLV-I infection. 5 The need for universal HTLV-I screening of all blood donations in Australia is currently under consideration. Japan and the United States both screen their blood donations and screening is now being introduced in many other countries. Laboratory screening for HTLV-I is complicated by the fact that the two most commonly used systems, ELlSA and particle agglutination, also coincidentally detect HTLV-II antibodies. 52 Distinguishing between HTLV-I and HTLV-II requires sophisticated laboratory investigation including western blotting, radioimmunoprecipitation and polymerase chain reaction. 52 ,53 The distinction is important as although HTLV-II has been isolated in two patients with T-cell hairy cell leukaemia, its pathogenic potential is largely unknown. 54, 55 
CYTOMEGALOVIRUS (CMV)
CMV is a member of the herpes virus family. It is a common infection although the geographic prevalence varies from 40% to 100%. 56 Primary CMV infection usually goes unnoticed unless the host is immunocompromised. Although easily transmitted, it is only a clinical problem in certain clinical situations. Severe clinical disease is seen when immunosuppressed CMV seronegative individuals become infected. CMV is the most frequent infection causing death in bone marrow transplantations, primarily through pneumonia. Other transplant patients, low birth weight premature neonates, splenectomised patients, and patients receiving immunosuppressive chemotherapy are also at increased risk. Evidence is also accumulating that CMV may contribute to disease progression in HIV. 57 When primary CMV infection occurs during pregnancy, the congenitally infected infant may experience severe disease which may be fatal. CMV infection remains as the major congenital infection causing mental retardation and deafness. 58 Prevention of transmission of CMV to these highrisk groups is achieved by selecting blood that is negative for CMV antibody. However, the supply of seronegative blood is limited due to high seroprevalance in donor populations. An alternative is to transfuse the blood through leukocyte filters but this is expensive and while effectiveness has been demonstrated in neonates, studies to evaluate efficacy in other situations are still being performed. 59, 60 B. R. WVLlE OTHER EXOTICA
Chagas' Disease
Chagas' Disease is caused by the protozoa, Trypanosomiasis cruzi and is endemic in South America.
Humans serve as a reservoir, although the parasite can be found in many kinds of wild animals. It is transmitted to humans from infected animals via bed bugs called reduvids, which are blood-sucking insects that deposit their contaminated faeces as they feed.
The organism has a predilection for myocardial cells and smooth muscle cells in the oesophagus and colon. Infection can occur through blood transfusion which is in fact the second most important mechanism in endemic areas. The risk of becoming infected after receiving blood or plasma from a seropositive donor varies from 12070 to 50%. 61 To prevent transmission by transfusion, blood donors with a positive serological test should be permanently deferred. Parasites survive for at least ten days in refrigerated citrated blood and have been recovered from frozen plasma. Gentian Violet or Crystal Violet, if added to the blood 24 hours prior to infusion, prevents infection.
Transmission of T. cruzi by transfusion is a major problem in Latin America and is receiving growing attention in the United States with its increasing Hispanic population. There have been at least two documented transmissions through blood transfusion in the United States. 62.63 In both cases the recipient had no history of travel to South America but had received a blood donation which had come from a donor native to Latin America. To date T. cruzi is not a known blood transfusion problem in Australia.
Lyme Disease
Lyme disease is caused by the spirochaete, Borrelia burgdorferi. The agent was cultured from the deer tick, Ixodes dammini in 1982 and from patients with Lyme disease in 1983. 64 It causes a classic localised skin rash, erythema chronicum migrans, and patients untreated or unrecognised go on to develop a protean illness with arthritic, neurologic or cardiac manifestations. Unlike Treponema pal/idum, the spirochaete of Lyme disease survives storage in blood components quite well. 65. Although no cases of transfusion-transmitted Lyme disease have been found, transmission by transfusion is at least theoretically possible. In America it has been decided that large scale testing of healthy donor blood is not indicated since transmission has not yet been documented and there is no reliable screening test. 66 Although having received considerable attention recently in the world literature, Lyme disease and the potential for transmission in Australia is even less certain although it should be noted that Lyme disease does occur down the east coast of the Australian continent. 676'1
lakob-Creut<feldt Disease
This disease, caused by a "slow" virus, has recently come to attention through transmission to people by human pituitary hormone extracts. 41 Donors who have received such extracts, for example growth hormone, are permanently deferred as blood donors. There has never been a reported case of transmission of Jacob-Creutzfeldt Disease through blood transfusion. 41 
CONCLUSION
The range of diseases described above is not meant to be exhaustive, and other organisms can, in fact, be transmitted by blood transfusion. This review has, however, covered the major organisms responsible for transfusion-transmitted disease and has discussed more unusual organisms currently receiving considerable attention in the literature.
The real issue regarding transfusion transmitted diseases is, of course, what is the risk of getting any infection through a blood transfusion? It remains likely that the risk of this equals effectively the risk of getting hepatitis C through transfusion in spite of receiving screened blood, as the risk of acquiring any other disorder through blood transfusion is so low that it would only be minimal compared with the remaining risk of hepatitis C. This risk is, of course, difficult to estimate. One could speculate that if the incidence of post-transfusion non-A and non-B hepatitis was already well under 1% prior to the introduction of hepatitis C screening, and if hepatitis C screening removes 90% of the infective donors from the pool, the remaining risk may be under 0.1 %.
Obviously, only careful epidemiological studies can accurately establish the actual risk, but it is certain the risk is now so low that if it prevents a patient accepting or receiving a blood transfusion, the transfusion probably was not clinically indicated in the first place.
